Accessibility: Skip TopNav
Patient response rates following treatment with CB-010, single dose at dose level 1, in the ANTLER Phase 1 trial
Footnote: data cutoff date of February 23, 2022, data collection ongoing, efficacy based on Lugano criteria
Format
PNG
Source
Caribou Biosciences, Inc.
Downloads
Original
Large
Medium
Small